May 23, 2017 / 10:43 AM / 5 months ago

BRIEF-Prometic says plasminogen administration shown to reduce ALI in acute pancreatitis model

May 23 (Reuters) - Prometic Life Sciences Inc:

* Says presents new data on PBI-4050 and plasminogen

* Prometic Life Sciences - PBI-4050 monotherapy and combination with nintedanib demonstrated promising results in treatment of idiopathic pulmonary fibrosis

* Says plasminogen administration shown to reduce acute lung injury (ALI) in an acute pancreatitis model Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below